{"id":"NCT03469349","sponsor":"Takeda","briefTitle":"Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB","officialTitle":"A Randomized, International, Multicenter, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Subjects With Peripheral Arterial Occlusive Disease Fontaine Stage IIB","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-01","primaryCompletion":"2019-05-28","completion":"2019-08-28","firstPosted":"2018-03-19","resultsPosted":"2020-10-28","lastUpdate":"2020-10-28"},"enrollment":366,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Peripheral Arterial Diseases"],"interventions":[{"type":"DRUG","name":"Actovegin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Actovegin 1200 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the efficacy and safety of actovegin in participants with peripheral arterial disease (PAD) Fontaine Stage IIB.","primaryOutcome":{"measure":"Percent Change From Baseline in Initial Claudication Distance (ICD) at Week 12","timeFrame":"Baseline up to Week 12","effectByArm":[{"arm":"Placebo","deltaMin":21.99,"sd":9.286},{"arm":"Actovegin 1200 mg","deltaMin":51.17,"sd":9.187}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0041"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":20,"countries":["Georgia","Kazakhstan","Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":182},"commonTop":["Nasopharyngitis","Diabetes mellitus","Pneumonia","Pyelonephritis chronic","Respiratory tract infection"]}}